Anticoagulants Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of anticoagulants Market

The anticoagulants market size was valued at USD 21.45 billion in 2019, and the market is now projected tgrow tUSD 80.29 billion by 2032, exhibiting a CAGR of 9.9% during the forecast period of 2020-2032.

The studies have revealed that COVID-19 played a major role in driving the anticoagulants market because anticoagulant treatments found application in the case of severe COVID-19 with thromboembolic conditions. The increased number of hospitalizations as well the use of anticoagulants for critical patients during the pandemic drove the demand higher. Nevertheless, the dynamics of distribution and organizational interruptions of healthcare services and supply an initial challenge for market expansion. Once the identified changes in patient and healthcare needs are fully understood, as well as additional therapeutic applications are developed for APNNs, the industry should return tfurther growth due tthe continually increasing incidence of cardiovascular diseases in the population. These factors kept the anticoagulants market growth stable.

A factor that defines the dynamics of the global market is the rising concern for cardiovascular health and the consequent launch of new therapeutic products. Cardiovascular treatment through therapeutics encompasses several components that may result tthe use of several types of Cardiovascular medications; however, blood thinning medications is an important component of Cardiovascular treatment. Several of the important market players have launched quite a number of anticoagulants tmeet the essential treatment requirements with regard tblood clots. For example, regulating an anticoagulant released by the Bristol-Myers Squibb Company and Pfizer Inc. known as Eliquis (apixaban). The drug has high sales and can adopt higher risk reduction compared tother counterparts in the global scenario. This boosted the anticoagulants market share.

Another emerging feature in the anticoagulants market is the switch tdirect oral anticoagulants because of their benefits in comparison with vitamin K inhibitors, such as warfarin. Apixaban and rivaroxaban for example, offer the understanding predictable pharmacokinetics; the DOACs does not require frequent monitoring; the management of DOACs is not as restricted by dietary interference when compared with warfarin. Also, the pharmaceutical companies are aiming at developing new applicability of DOACs including the usage in cancer-mediated thrombosis and the venous thromboembolism. This trend is mitigating the increasing need for safe and convenient anticoagulation treatments.

Comprehensive Analysis of Anticoagulants Market

The anticoagulants market is responding quite an unprecedented rate of growth because of its market segmentation. This indicators growth in different regions by substituting the major forces of supply and demand which define the shape of local pharmacy benefit management market. Therefore, they are logically divided int3 Segments, by disease indication outlook, by route of administration outlook and by distribution channel outlook. The global blood thinning medication market is classified on the basis of the disease indication as pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), heart attacks, and others. According tthe mode of application, the global market can further be distinguished intoral and injectable. Currently, oral anticoagulants are believed tbe recording the highest market revenue in the course of the forecast period. Oral anticoagulant is the oldest and most traditional route of administering anticoagulant and is expected tgrow in the future within the period of the forecast. According tthe distribution channel, the global market can be categorized inthospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacies segment is expected tprocure a larger share because these anticoagulants are riskier and are used in lifelong therapy after proper diagnosis which occurs at such places.

North America generated a revenue of USD 10.10 billion in 2018. Due tescalating incidences of cardiovascular diseases, needing treatment via anticoagulants, and new product launches across the region, growth will occur in the market area. Apart from this, the raising research and development undertakings, coupled with the rising concern and high prevalence of risk factors such as obesity and diabetes across the populations in North America are likely tpropel the market size during the given period.

Bristol-Myers Squibb Company [U.S.], Pfizer Inc. [U.S], Bayer AG [Germany], Janssen Pharmaceuticals, Inc. [U.S.], Eisai Co., Ltd. [Japan] are significant players in the pharmaceutical market. They are the key player that ensures the industry's success while still having tkeep pace with their innovation in product and services. They offer a competitive zone that incites the growth of technologies and quality assurance. They operate on a global scale and have a wide range of product lines ensuring that the market players compete on a fair playing field bringing in innovations that result in the market's evolution.

In February 2021, according tthe study conducted at Stony Brook, coupled therapy with an anticoagulation therapy depending on the blood serum D-dimer levels proved tlower mortality among critically ill patients suffering from Covid-19.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Disease Indication

Pulmonary Embolism (PE)

Deep Vein Thrombosis (DVT)

Atrial Fibrillation

Heart Attacks

Others

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)